Key result
DAAs strongly improve neurologic conditions in chronic hepatitis C, particularly after attaining SVR.
Why the study?
Neurologic and neuropsychiatric manifestations are common in chronic hepatitis C and the impact of direct-acting antivirals on these neurologic disorders needed systematic evaluation.
Does direct-acting antiviral (DAA) treatment improve neurologic disorders in patients with chronic hepatitis C?
Systematic Review
Does direct-acting antiviral (DAA) treatment improve neurologic disorders in patients with chronic hepatitis C?
Direct-acting antiviral therapy for chronic hepatitis C is associated with significant improvement and regression of HCV-induced neurologic disorders.
Answers are grounded in this paper and cite their sources.
Unexplained neurologic symptoms may warrant HCV testing; extends awareness of extrahepatic manifestations but leaves open prospective validation.
INTRODUCTION: Neurologic and neuropsychiatric manifestations sometimes provide the first evidence of an unknown HCV infection. These conditions develop with a variable ranging of morbidity, including: "brain fog," fatigue, subtle cognitive and attention impairment, but also with more severe complications or acute presentation, like encephalomyelitis, encephalopathy, stroke and peripheral nerves involvement. EVIDENCE ACQUISITION: We performed a systematic literature search on PubMed, Cochrane Library and Web of Science databases for articles only in English language, that assessed the relationship between "DAA treatment and neurologic disorders" and after the attainment of SVR in full reports of cases that received the DAA schedule from January 2015 to December 2019. The following terms were used: "chronic Hepatitis C," "HCV," "DAA," "direct-acting antiviral," "SVR," "sustained virologic response," peripheral neuropathy" and "neurologic diseases or disorders." EVIDENCE SYNTHESIS: HCV infection does not only involve the liver, causing cirrhosis and hepatocellular carcinoma (HCC), but also induces extrahepatic manifestations (EHM), mainly due to a complex immune disease, that damage small and medium vessels, called "mixed cryoglobulinemic vasculitis" (MCV). This kind of mechanism generates most of the HCV-induced neurological damages. Since 2015, the availability of direct-acting antiviral (DAA) oral molecules interfering with HCV replication has completely revolutionized therapeutic options and the target population, which now includes patients aged 12 to 80 years and with advanced liver disease. Relevant was the highlighted DAA effectiveness by achievement of a sustained virologic response (SVR) in about 95% of cases, showing a great tolerability. CONCLUSIONS: This favorable effect has arisen in a wide category of patients infected by HCV, including subjects with cirrhosis and complications and/or with EHM, who showed a significant improvement of their symptoms and the disease regression. In this concise review, we examine the clinical outcomes after the introduction of the DAA for the treatment of chronic hepatitis C (CHC), focusing on the neurologic disorders and concluding that there is a strong amelioration of neurologic conditions in several cases, particularly, after attaining the viral eradication with a favorable course in most treated cases.
No takes yet. Share an insight, caveat, or question.
Chemello et al. (2021) conducted a systematic review in Chronic hepatitis C with neurologic disorders. Direct-acting antivirals (DAA) was evaluated on Clinical outcomes and neurologic disorders. Direct-acting antiviral therapy for chronic hepatitis C resulted in a strong amelioration of neurologic conditions, particularly after attaining sustained virologic response.
Synapse has enriched 10 related papers. Consider them for comparative context: